Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 90.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (10.7%)
  • Dividend yield for the last twelve months 3.2%
  • Free cash flow yield -1.0% (LTM)
  • Share price is 9.5% higher than minimum and 13.7% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (12.5x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (-0.3%)155.5999
year average price 156.16  


year start price 145.48 2024-07-08

min close price 142.06 2025-01-10

max close price 167.70 2025-03-10

current price 155.64 2025-07-07
Common stocks: 2 631 399 832

Dividend Yield:  3.2%
FCF Yield LTM: -1.0%
EV / LTM EBITDA: 12.5x
EV / EBITDA annualized: 6.9x
Last revenue growth (y/y):  +2.4%
Last growth of EBITDA (y/y):  +178.6%
Historical revenue growth:  +0.3%
Historical growth of EBITDA:  +21.1%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 409 446
Net Debt ($m): 13 471
EV (Enterprise Value): 422 917
EBITDA LTM ($m): 33 900
EV / LTM EBITDA: 12.5x
Price to Book: 5.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-07247wallst.com

3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend

2025-07-07zacks.com

Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?

2025-07-04247wallst.com

2 Bulletproof Dividend Stocks to Buy in July

2025-07-03zacks.com

Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

2025-07-03zacks.com

Johnson & Johnson (JNJ) Could Be a Great Choice

2025-07-03globenewswire.com

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

2025-06-30seekingalpha.com

Johnson & Johnson: Patience Will Be Rewarded

2025-06-27fool.com

Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.

2025-06-26zacks.com

J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?

2025-06-24seekingalpha.com

Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data